| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/22/2006 | US20060135606 Use of carnitines for the prevention and/or treatment of disorders caused by the andropause |
| 06/22/2006 | US20060135605 Intermediates in producing phenoxyacetic acid derivatives and method of using the same |
| 06/22/2006 | US20060135604 Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use |
| 06/22/2006 | US20060135603 Contacting IKK with a compound that interacts with the cysteine at position 179 of IKK, wherein compound is selected from the group consisting of cyclopentenones and substituted cyclopentenones |
| 06/22/2006 | US20060135602 Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfphonates) and compositions containing same |
| 06/22/2006 | US20060135601 N-(2,2,2-Trifluoro-ethyl)-N-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-cyclohexyl]-benzenesulfonamide; binds to LXR alpha and LXR beta agonists |
| 06/22/2006 | US20060135600 Brain-derived neurotrophic factor (BDNF) and antioxidant Neu 2000 which is 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethylbenzylamino)benzoic acid; synergistic; neuroprotectant |
| 06/22/2006 | US20060135599 Use for pharmaceutical composition |
| 06/22/2006 | US20060135598 citirus-based furocoumarins; for dietary supplements or medicinal foods |
| 06/22/2006 | US20060135597 Administering a bithiophene substituted by a carboxyalkyl group and a pyridinyl or pyrimidinyl group to treat irritable bowel syndrome, chronic heart failure, angina, cardiac infarction, cerebral infarction, pollakiuria, urinary incontinence, or, cerebral ischemia |
| 06/22/2006 | US20060135596 Amorphous form of a drug |
| 06/22/2006 | US20060135595 Compounds are significantly cytotoxic, show unexpectedly high water solubility and bioavailability and are effective when used in combination with other anticancer drugs like paclitaxel or its analogs;Lithium; 2-(N'-methyl-N'-thiobenzoyl-hydrazinocarbonyl)-1-(methyl-thiobenzoyl-hydrazono)-ethanolate |
| 06/22/2006 | US20060135594 Dihydropyrrole derivatives; 3-{(2S)-4-(2,5-difluorophenyl)-1-[(dimethylamino)carbonyl]-2,5-dihydro- 1H-pyrrol-2-yl}phenyl dihydrogen phosphate; anticarcinogenic agents; cellular proliferative diseases; specificity; side effect reduction |
| 06/22/2006 | US20060135593 N-acyl nitrogen heterocyles as ligands of peroxisome proliferator-activated receptors |
| 06/22/2006 | US20060135592 Indolinones and their use as antiproliferative agents |
| 06/22/2006 | US20060135591 Modulators of CRTH2 activity |
| 06/22/2006 | US20060135590 Selected fused pyrrolocarbazoles |
| 06/22/2006 | US20060135589 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors |
| 06/22/2006 | US20060135588 Preventive and/or therapeutic drugs for inflammatory intestinal diseases |
| 06/22/2006 | US20060135587 Method and compounds for promoting healing and reducing inflammation |
| 06/22/2006 | US20060135586 For pegylation of biodrugs and drugs; for example, polyethylene glycol with pyridyldithioalkoxy end groups; allows target amino acid for attachment, to be cysteine instead of lysine which can inactive some peptide drugs |
| 06/22/2006 | US20060135585 Compounds and methods for thiol-containing compound efflux and cancer treatment |
| 06/22/2006 | US20060135584 Novel imidazole alcohol compound, process for producing the same, and surface-treating agent comprising the same |
| 06/22/2006 | US20060135583 e.g. 4-[3'-(3''-aminosulfonylpropyl)-4',4'-dimethyl-5'-oxo-2'-thioxo-1'-imidazolidinyl]-2-trifluoromethylbenzonitrile; anti-androgen agent which has a sufficient antagonistic effect and reduced side effect profile |
| 06/22/2006 | US20060135582 Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof |
| 06/22/2006 | US20060135581 Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors |
| 06/22/2006 | US20060135580 One step reaction of compound such as 3,5-dimethyl-isoxazole with butlyllithium and (3,5-di-tert-butyl)-4-hydroxybenzaldehyde, recrystallization/dehydration alcohol in the presence of a base to give (E)-5-[2-(3,5-di-tert-butyl-4-hydroxyphenyl)vinyl]-3-methylisoxazole |
| 06/22/2006 | US20060135579 amino alcohols; selective ribonucleic acid (RNA) binding agents; detecting the binding of small molecules to T-box antiterminator model mRNAs; screening for microbiocidal drug targets; use disinfecting; antiviral, anti-HIV; e.g. use of 1,2-dihydroxy-3-amino-4-phenylbutane |
| 06/22/2006 | US20060135578 Five-membered heterocyclic compounds |
| 06/22/2006 | US20060135577 EDG (Endothelial differentiation gene)-2 antagonist; chronic asthma, glomerular nephritis, obesity, prostate hyperplasia, arteriosclerosis, atopic dermatitis; (1) 3-(N-((2-(2-((4-chlorobenzylamino)carbonyl)phenyl)phenyl)carbonyl)-N-(2-(2-methoxyphenyl)ethyl)amino)propanoic acid |
| 06/22/2006 | US20060135576 2-Amino-(imidazole, thiazole, or oxazole) derivatives; tyrosine kinase, endothelial growth factor, angiogenesis and fibroblast growth factor inhibitors; anticarcinogenic and antidiabetic agents |
| 06/22/2006 | US20060135575 2-Acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof |
| 06/22/2006 | US20060135574 Novel uses for estrogen beta agonists |
| 06/22/2006 | US20060135573 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof |
| 06/22/2006 | US20060135572 Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis |
| 06/22/2006 | US20060135571 Imidazo(2,1-b)-1,3,4-thiadiazole sulfoxides and sulfones |
| 06/22/2006 | US20060135570 Cyclic sulfamides for inhibiton of gamma-secretase |
| 06/22/2006 | US20060135569 Use of benzisoselenazolone compounds against ischemic myocardial damage |
| 06/22/2006 | US20060135568 Methods of treating microbial infections in humans and animals |
| 06/22/2006 | US20060135567 Comprehensive pharmacologic therapy for treatment of obesity |
| 06/22/2006 | US20060135566 E.g., N-[5-(2-Benzoylamino-4-pyridyl)-4-(3,5-dimethylphenyl)-1,3-thiazol-2-yl]acetamide,; the compounds have adenosine A3 receptor antagonistic activity, a p38 MAP kinase inhibitory action, and a TNF- alpha production-inhibitory action |
| 06/22/2006 | US20060135565 Crystalline form of rabeprazole sodium |
| 06/22/2006 | US20060135563 Method for treating HIV infection through co-administration of tipranavir and SCH-417690 |
| 06/22/2006 | US20060135562 Method for treating HIV infection through co-administration of tipranavir and darunavir |
| 06/22/2006 | US20060135561 4-Aminopiperidine derivatives |
| 06/22/2006 | US20060135560 Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
| 06/22/2006 | US20060135559 Novel imidazoline compounds |
| 06/22/2006 | US20060135558 Aroyl-piperidine derivatives |
| 06/22/2006 | US20060135557 neurodegenerative diseases such as Alzheimer's disease, apoplexy and brain ischemic injuries |
| 06/22/2006 | US20060135556 Non-nucleoside reverse transcriptase inhibitors |
| 06/22/2006 | US20060135555 Ring fused pyrazole derivatives as CRF antagonists |
| 06/22/2006 | US20060135554 Novel compounds |
| 06/22/2006 | US20060135553 Imidazole derivatives |
| 06/22/2006 | US20060135552 1-(2-Methyl-4-phenyl-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-b]pyridin-3-yl)-ethanone for example; central nervous system disorders including anxiety, depression, epilepsy, schizophrenia, cerebral palsy, post-traumatic stress disorder, spinal cord injury, multiple sclerosis |
| 06/22/2006 | US20060135551 for treating or preventing conditions or diseases associated with lipoprotein metabolism |
| 06/22/2006 | US20060135550 Rapamycin derivatives and the uses thereof in the treatment of neurological disorders |
| 06/22/2006 | US20060135549 Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative,and inflammatory disorders |
| 06/22/2006 | US20060135548 Such as pimecrolimus and tacrolimus |
| 06/22/2006 | US20060135547 Combining a solution of desloratadine in an organic solvent selected from the group consisting of a C2 to C5 alkyl acetate, butanol, isobutanol, toluene and chloroform with a C5 to C12 hydrocarbon to precipitate the mixture, recovering the mixture |
| 06/22/2006 | US20060135546 Methods for the purification of 20(S)- camptothecin |
| 06/22/2006 | US20060135545 derivatives of acronycine such as cis-2-cinnamoyloxy-1-hydroxy-6-methoxy-3,3,14-trimethyl-1,2,3,14-tetrahydro-1H-benzo[b]pyrano[3,2-h]acridin-7-one, used as antitumor agents |
| 06/22/2006 | US20060135544 A Suzuki coupling reaction of 2-butyl-3-(4-bromobenzyl)-1,3-diazaspiro[4.4]non-1-ene-4-one and 2-((1-trityl-1H-tetrazol-5-yl))phenylboronic acid in a basic solvent system with a palladium or nickel complex catalyst |
| 06/22/2006 | US20060135543 N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors |
| 06/22/2006 | US20060135542 For cardiovascular disease (such as Kawasaki syndrome and moyamoya) in children |
| 06/22/2006 | US20060135541 (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer |
| 06/22/2006 | US20060135540 PPAR active compounds |
| 06/22/2006 | US20060135539 Thienopyridazinones and their use in modulation of autoimmune disease |
| 06/22/2006 | US20060135537 Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
| 06/22/2006 | US20060135536 Ion channel modulating activity I |
| 06/22/2006 | US20060135535 Phosphodiesterase 4 inhibitors |
| 06/22/2006 | US20060135534 Pyrazine based inhibitors of glycogen synthase kinase 3 |
| 06/22/2006 | US20060135533 Compound preparation for dizziness |
| 06/22/2006 | US20060135532 Anticoagulants; antithrombotic agents in the treatment and prevention of thrombosis |
| 06/22/2006 | US20060135531 Modulators of dopamine neurotransmission |
| 06/22/2006 | US20060135530 Such as (2E)-3-[3-(aminomethyl)-2-isobutyl-4-(4-methylphenyl)quinolin-6-yl]acrylamide; dipeptidyl peptidase IV inhibitors; diabetes, obesity, glucose intolerance |
| 06/22/2006 | US20060135529 Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof |
| 06/22/2006 | US20060135528 For treatment and/or prevention of diseases which are associated with the modulation of H3 receptors; treatment of obesity; N-[2-(4-ethyl-piperazin-1-yl)-pyridin-4-yl]-propionamide, 1-[2-(4-ethyl-piperazin-1-yl)-pyridin-4-yl]-3-propyl-urea |
| 06/22/2006 | US20060135527 Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents |
| 06/22/2006 | US20060135526 Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists |
| 06/22/2006 | US20060135525 Pyrazolopyrimidine compound and a process for preparing the same |
| 06/22/2006 | US20060135524 delta-opioid receptor agonists as analgesics having reduced side effects and antagonists as immunosuppressants, antiinflammatory agents, neurological, psychiatric , urological and reproductive conditions; e.g. 10-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenoxazine-3-carboxylic acid diethylamide |
| 06/22/2006 | US20060135523 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator |
| 06/22/2006 | US20060135522 Tricyclic delta-opioid modulators |
| 06/22/2006 | US20060135521 Administering racemic reboxetine or a salt thereof for inhibition of norepinephrine reuptake |
| 06/22/2006 | US20060135520 Method of treating peripheral neuropathy |
| 06/22/2006 | US20060135519 5-aryltetrazole compounds and compositions thereof |
| 06/22/2006 | US20060135518 administering pyrimidine derivatives such as N-(1H-indol-3-ylmethylene)-N'-{6-morpholin-4-yl-2-[2-(pyridin-3-yloxy)-ethoxy]-pyrimidin-4-yl}-hydrazine, to inhibit the production of interleukins, useful for treating autoimmune and inflammatory disorders |
| 06/22/2006 | US20060135517 Imidazolopyridines and methods of making and using the same |
| 06/22/2006 | US20060135516 3-(Carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors |
| 06/22/2006 | US20060135515 Heterocyclic amides and their use treating thromboembolic diseases and tumors |
| 06/22/2006 | US20060135514 Pyrazolo[1,5-a]pyrimidine derivatives |
| 06/22/2006 | US20060135513 Methods of treating tumors |
| 06/22/2006 | US20060135512 Aminocycloalkanes as DPP-IV inhibitors |
| 06/22/2006 | US20060135511 Benzodiazepine cgrp receptor antagonists |
| 06/22/2006 | US20060135510 Use of amprenavir as a radiation sensitizer |
| 06/22/2006 | US20060135509 10-(3-(N,N-dimethylamino)propyl)phenothiazine; replaces or enhances the function of SMN to alleviate or reduce a phenotype of a cell with low SMNprotein levels; gene therapy; neurogenative diseases; psychological disorders;spinal muscular atrophy |
| 06/22/2006 | US20060135508 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 06/22/2006 | US20060135507 Therapeutic agent for overactive bladder involved in aging |
| 06/22/2006 | US20060135506 Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders |
| 06/22/2006 | US20060135505 N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[3-piperidin-1-yl-4-(trifluoromethyl)benzyl]urea; urinary incontinence, overactive bladder, pain, nerve injury, ischemia, neurodegeneration, stroke, inflammatory disorders, asthma and chronic obstructive pulmonary disease |